Optimizing cervical cancer prevention strategies in the United States

Gynecologic Oncology

Volumn 127, Issue 3, 2012, Pages 437-439

  Castle, Philip E ^a   Schmeler, Kathleen M ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

BREAST FEEDING EDUCATION; CANCER PREVENTION; CANCER RISK; CANCER STAGING; CARCINOGENESIS; COLPOSCOPY; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; GENE OVEREXPRESSION; GENOTYPE; HEALTH CARE COST; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; LIFE EXPECTANCY; NONHUMAN; PAPILLOMAVIRUS INFECTION; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEXUALLY TRANSMITTED DISEASE; UNITED STATES; UTERINE CERVIX CANCER; VACCINATION;

EID: 84868561698     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.10.012     Document Type: Editorial

References (27)

1. M. Schiffman, P.E. Castle, J. Jeronimo, A.C. Rodriguez, and S. Wacholder Human papillomavirus and cervical cancer Lancet 370 2007 890 907
2. C.M. Wheeler, W.C. Hunt, J. Cuzick, E. Langsfeld, A. Pearse, and G.D. Montoya A population-based study of human papillomavirus genotype prevalence in the United States: baseline measures prior to mass human papillomavirus vaccination Int J Cancer 10 2012
3. S. de Sanjose, M. Diaz, X. Castellsague, G. Clifford, L. Bruni, and N. Munoz Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis Lancet Infect Dis 7 2007 453 459
4. S.D. Datta, L.A. Koutsky, S. Ratelle, E.R. Unger, J. Shlay, and T. McClain Human papillomavirus infection and cervical cytology in women screened for cervical cancer in the United States, 2003-2005 Ann Intern Med 148 2008 493 500
5. S. Vaccarella, S. Franceschi, R. Herrero, N. Munoz, P.J. Snijders, and G.M. Clifford Sexual behavior, condom use, and human papillomavirus: pooled analysis of the IARC human papillomavirus prevalence surveys Cancer Epidemiol Biomarkers Prev 15 2006 326 333
6. M. Plummer, M. Schiffman, P.E. Castle, D. Maucort-Boulch, and C.M. Wheeler A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion J Infect Dis 195 2007 1582 1589
7. A.C. Rodriguez, M. Schiffman, R. Herrero, S. Wacholder, A. Hildesheim, and P.E. Castle Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections J Natl Cancer Inst 100 2008 513 517
8. P.E. Castle, A.C. Rodriguez, R.D. Burk, R. Herrero, S. Wacholder, and M. Alfaro Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study BMJ 339 2009 b2569 10.1136/bmj.b2569.:b2569;2009
9. S.K. Kjaer, K. Frederiksen, C. Munk, and T. Iftner Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence J Natl Cancer Inst 2010
10. J. Koshiol, L. Lindsay, J.M. Pimenta, C. Poole, D. Jenkins, and J.S. Smith Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis Am J Epidemiol 168 2008 123 137
11. M.R. McCredie, K.J. Sharples, C. Paul, J. Baranyai, G. Medley, and R.W. Jones Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study Lancet Oncol 9 2008 425 434
12. Cervical cancer inquiry N Z Nurs Forum 16 1988 5 6
13. T.C. Wright Jr., and M. Schiffman Adding a test for human papillomavirus DNA to cervical-cancer screening N Engl J Med 348 2003 489 490
14. A. Hildesheim, R. Herrero, S. Wacholder, A.C. Rodriguez, D. Solomon, and M.C. Bratti Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial JAMA 298 2007 743 753
15. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions N Engl J Med 356 2007 915 927
16. P.E. Castle, M. Schiffman, R. Herrero, A. Hildesheim, A.C. Rodriguez, and M.C. Bratti A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica J Infect Dis 191 2005 1808 1816
17. A.F. Rositch, A.E. Burke, R.P. Viscidi, M.I. Silver, K. Chang, and P.E. Gravitt Contributions of recent and past sexual partnerships on incident human papillomavirus detection: acquisition and reactivation in older women Cancer Res 2012
18. J.J. Kim, and S.J. Goldie Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States BMJ 339 2009 b3884 10.1136/bmj.b3884.:b3884;2009
19. H.W. Chesson, D.U. Ekwueme, M. Saraiya, E.F. Dunne, and L.E. Markowitz The cost-effectiveness of male HPV vaccination in the United States Vaccine 29 2011 8443 8450
20. T. Kirby Australia to be first country to vaccinate boys against HPV Lancet Oncol 13 2012 e333
21. S.S. de, W.G. Quint, L. Alemany, D.T. Geraets, J.E. Klaustermeier, and B. Lloveras Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study Lancet Oncol 11 2010 1048 1056
22. D. Saslow, D. Solomon, H.W. Lawson, M. Killackey, S.L. Kulasingam, and J. Cain American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer CA Cancer J Clin 62 2012 147 172
23. M.J. Khan, P.E. Castle, A.T. Lorincz, S. Wacholder, M. Sherman, and D.R. Scott The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice J Natl Cancer Inst 20 97 2005 1072 1079
24. F. Carozzi, M. Confortini, P.D. Palma, M.A. Del, A. Gillio-Tos, and M.L. De Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial Lancet Oncol 2008
25. K. Cuschieri, and N. Wentzensen Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia Cancer Epidemiol Biomarkers Prev 17 2008 2536 2545
26. J. Schweizer, P.S. Lu, C.W. Mahoney, M. Berard-Bergery, M. Ho, and V. Ramasamy Feasibility study of a human papillomavirus e6 oncoprotein test for diagnosis of cervical precancer and cancer J Clin Microbiol 48 2010 4646 4648
27. Y.S. Yang, K. Smith-McCune, T.M. Darragh, Y. Lai, J.H. Lin, and T.C. Chang Direct human papillomavirus e6 whole-cell enzyme-linked immunosorbent assay for objective measurement of e6 oncoproteins in cytology samples Clin Vaccine Immunol 19 2012 1474 1479